Navigation Links
Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
Date:6/11/2015

SAN DIEGO, June 11, 2015 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen). Under the agreement, facilitated by J&J Innovation, the parties will work together to develop and commercialize RNA-based drug products for the treatment of specified diseases using Arcturus' UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery platform. Arcturus will receive an upfront payment, R&D support, and pre-clinical, development and sales milestone payments, as well as royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program. The collaboration brings together Arcturus' expertise and intellectual property in the field of RNA medicines along with Janssen's clinical development, regulatory, and marketing proficiency.

"We are pleased to be collaborating with a top tier pharmaceutical company like Janssen," said Joseph E. Payne, President & CEO of Arcturus Therapeutics. "Arcturus is thrilled to be working together with Janssen to identify an RNA treatment for one of the pharmaceutical industry's most challenging disease targets."

About Arcturus Therapeutics, Inc.

Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies – UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics.  The company owns unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (34 patents and patent applications, issued in the U.S. and other countries).  The patented UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. For more information, visit www.ArcturusRx.com.

Logo - http://photos.prnewswire.com/prnh/20130531/MM24393LOGO

 


'/>"/>
SOURCE Arcturus Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
2. Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
3. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
4. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
5. Symbiomix Therapeutics Doses First Patient in Confirmatory Phase 3 Pivotal Study of Lead Drug Candidate SYM-1219 for Bacterial Vaginosis
6. vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes
7. Asia-Pacific Rheumatoid Arthritis Therapeutics Markets 2015-2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
8. Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches
9. Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone
10. GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines
11. Pivotal Therapeutics Announces First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2020)... ... September 03, 2020 , ... Using Analysis of Variance — ... Sept. 17, 2020, 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/anova , How much would ... , While one can’t become one in 90 minutes, one can master a powerful ...
(Date:9/1/2020)... SANTA CLARA, Calif. (PRWEB) , ... September 01, ... ... diagnostics, and analytical laboratory technologies, will host the Agilent Science and Technology ... , During this two-day symposium, Agilent will open a suite of Live webinars ...
(Date:9/1/2020)... , ... September 01, 2020 , ... September is National ... accounting for more deaths than any other cancer of the female reproductive system. ... with ovarian cancer and about 14,000 women will die from this disease. Throughout ...
Breaking Medicine Technology:
(Date:9/1/2020)... ... ... Feeding Matters , the first organization in the world dedicated to ... to announce that the U.S. Centers for Disease Control and Prevention (CDC) has officially ... of the U.S. International Classification of Diseases (ICD ) on October 1, 2021. ...
(Date:8/31/2020)... N.J. (PRWEB) , ... August 31, 2020 , ... Just found out your dear friend ... It’s heartbreaking when your friend or family member shares their diagnosis. Once the shock wears ... I say the wrong thing? What are the best ways to help? Words are failing ...
(Date:8/31/2020)... ... 31, 2020 , ... Smile Brands Inc., one of the ... States, today announced the grand opening of another affiliated Bright Now! Dental ... convenient hours, a comfortable office, and full-service care at the new Beaumont location. ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... outcomes for patients with advanced heart failure, today announced that the company has ... amount of $555,358 from the National Heart, Lung, and Blood Institute of the ...
(Date:8/28/2020)... GROVE, Ill. (PRWEB) , ... August 28, 2020 ... ... COVID-19, The Nourished Group set out to continue helping the specialty-diet ... attendees can discover new gluten-free products, get coupons, enter giveaways, chat with brands ...
Breaking Medicine News(10 mins):